摘要
卵巢癌是一种发病率较高的女性生殖系统恶性肿瘤,早期病情隐匿,症状不典型,多数患者确诊时已达晚期,严重威胁着女性的生命健康。众多信号通路参与卵巢癌的形成、发展过程,其中磷脂酰肌醇3-激酶(PI3K)/蛋白激酶B(Akt)信号通路是关键的调控通路之一。近年来,中医药抗肿瘤以其安全性高、不良反应少等优势受到广泛的重视,其中对于中药单体的研究也日益受到人们的关注。分子生物学研究表明,中药单体可通过调控多个靶点对肿瘤发挥作用。回顾文献,通过对多个数据库进行检索,发现中药单体可以通过调控PI3K/Akt信号通路对卵巢癌细胞生长增殖、侵袭和迁移、凋亡、自噬、逆转耐药等过程发挥着重要的作用。根据现有的研究显示,中药单体对于卵巢癌具有一定的疗效,但依然存在诸多问题。尽管中药单体在卵巢癌治疗方面的一些机制已经明确,但这些中药单体也仅仅停留在体内荷瘤裸鼠及体外细胞实验研究层面,未来需要更深入的研究。另外,在以后的研究中,还可将卵巢癌的辨证分型与靶向治疗的中药性味归经、功效主治相互联系,进一步发扬传统中医药的优势。基于国内外的研究现状,该文归纳总结了中药单体通过调控PI3K/Akt信号通路干预卵巢癌的研究进展,以期为中药单体的深入研究提供参考依据,为开拓中药靶向治疗卵巢癌的研究提供重要思路。
Ovarian cancer is a kind of malignant tumor in female reproductive system with a high incidence. This disease is insidious at its early stage and the symptoms are not typical. Most of the patients have reached advanced stage by the time of diagnosis,seriously threating women’s life and health. Many signaling pathways are involved in the formation and development of ovarian cancer, among which the phosphatidylinositol 3-kinase(PI3K)/protein kinase B(Akt)signaling pathway is one of the key regulatory pathways. In recent years,traditional Chinese medicine(TCM)has obtained wide attention in treatment of tumors due to its advantages of high safety and less adverse reactions,and more and more attention has been paid to the study of TCM monomers. Molecular biology studies have shown that TCM monomers can play a role against tumor by regulating multiple targets. By reviewing the literature and searching several databases,we found that TCM monomer can play an important role in the growth,proliferation,invasion and migration,apoptosis,autophagy and reversal of drug resistance of ovarian cancer cells by regulating PI3 K/Akt signaling pathway. According to the existing studies,TCM monomers have a certain effect on ovarian cancer,but there are still many problems. Although the mechanisms of some TCM monomers have been clarified in the treatment of ovarian cancer, such TCM monomers are only limited to the tumor-bearing nude mice in vivo and experimental studies on in vitro cells,and further studies are needed in the future. In addition,in the future researches,ovarian cancer syndrome differentiation and targeted therapy can be linked to the TCM flavors,efficacy and indications to further develop the advantages of TCM. Based on the current research situation at home and abroad,this paper summarized the research progress of targeted intervention of TCM monomers in ovarian cancer by regulating PI3K/Akt signaling pathway,in order to provide reference for further research of TCM monomers,and provide important ideas for the development of targeted treatment of ovarian cancer with TCM.
作者
徐佳越
郭滢
杨爽
韩凤娟
XU Jia-yue;GUO Ying;YANG Shuang;HAN Feng-juan(Heilongjiang University of Chinese Medicine,Harbin 150040,China;The First Affiliated Hospital of Heilongjiang University of Chinese Medicine,Harbin 150040,China)
出处
《中国实验方剂学杂志》
CAS
CSCD
北大核心
2021年第8期218-227,共10页
Chinese Journal of Experimental Traditional Medical Formulae
基金
国家自然科学基金面上项目(82074484)
黑龙江省自然科学基金项目(ZD2018020)
黑龙江省中医药科研项目(ZHY19-018)。